Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE Trial
Nyxoah (NYXH) initiated its U.S. post-approval BREATHE study with the first patient implanted using the Genio system for obstructive sleep apnea treatment. The study will enroll up to 229 patients across 25 U.S. centers over five years to generate real-world evidence supporting physician adoption and payer reimbursement. Despite the milestone, NYXH shares fell approximately 8% following the announcement.